This company listing is no longer active
TAIP.Y Stock Overview
Through its subsidiaries, researches, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) drugs and prescription pharmaceutical products in Japan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Taisho Pharmaceutical Holdings Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.00 |
| 52 Week High | US$15.52 |
| 52 Week Low | US$8.88 |
| Beta | 0.46 |
| 1 Month Change | 16.67% |
| 3 Month Change | 6.87% |
| 1 Year Change | 47.21% |
| 3 Year Change | 0.29% |
| 5 Year Change | -26.32% |
| Change since IPO | -27.46% |
Recent News & Updates
Recent updates
Shareholder Returns
| TAIP.Y | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -0.03% | 1.3% |
| 1Y | 47.2% | 1.8% | 24.4% |
Return vs Industry: TAIP.Y exceeded the US Pharmaceuticals industry which returned 26.5% over the past year.
Return vs Market: TAIP.Y exceeded the US Market which returned 22% over the past year.
Price Volatility
| TAIP.Y volatility | |
|---|---|
| TAIP.Y Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 10.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.6% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: TAIP.Y has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine TAIP.Y's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1912 | 8,784 | Akira Uehara | www.taisho-holdings.co.jp |
Taisho Pharmaceutical Holdings Co., Ltd., through its subsidiaries, researches, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) drugs and prescription pharmaceutical products in Japan and internationally. It operates through Self-Medication Operation Group and Prescription Pharmaceutical Operation Group segments. The company offers OTC drugs, quasi-drugs, food products, and general medical and hygiene supplies, such as Lipovitan series of energy drinks; the Pabron series of cold remedies and sinus treatments; the RiUP series of hair re-growth treatment products; the Taisho Kampo series of gastrointestinal treatment products; the Colac series of laxative products; the Naron series and other products for antipyretic analgesics; the Preser series of hemorrhoid treatment products; Hapacol, Efferalgan, Dafalgan, and Tempra for antipyretic analgesics; Counterpain topical anti-inflammatory analgesics; Vitacilina, a dermatological treatment product; and VICKS, a cough suppressant throat lozenges and medicated drops.
Taisho Pharmaceutical Holdings Co., Ltd. Fundamentals Summary
| TAIP.Y fundamental statistics | |
|---|---|
| Market cap | US$4.59b |
| Earnings (TTM) | US$53.33m |
| Revenue (TTM) | US$2.03b |
86.1x
P/E Ratio2.3x
P/S RatioIs TAIP.Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TAIP.Y income statement (TTM) | |
|---|---|
| Revenue | JP¥320.39b |
| Cost of Revenue | JP¥137.22b |
| Gross Profit | JP¥183.17b |
| Other Expenses | JP¥174.74b |
| Earnings | JP¥8.42b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 25.68 |
| Gross Margin | 57.17% |
| Net Profit Margin | 2.63% |
| Debt/Equity Ratio | 0% |
How did TAIP.Y perform over the long term?
See historical performance and comparisonDividends
1.1%
Current Dividend Yield97%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/07/15 22:42 |
| End of Day Share Price | 2024/07/15 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Taisho Pharmaceutical Holdings Co., Ltd. is covered by 16 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Atsushi Seki | Barclays |
| Ritsuo Watanabe | BofA Global Research |
| Hidemaru Yamaguchi | Citigroup Global Markets Japan Inc. |